TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Get Free Report) saw a large increase in short interest in October. As of October 30th, there was short interest totaling 16,244 shares, an increase of 48.9% from the October 15th total of 10,910 shares. Based on an average daily volume of 1,308 shares, the short-interest ratio is presently 12.4 days.
Hedge Funds Weigh In On TriSalus Life Sciences
An institutional investor recently bought a new position in TriSalus Life Sciences stock. State Street Corp purchased a new position in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 610,963 shares of the company’s stock, valued at approximately $2,780,000.
TriSalus Life Sciences Trading Up 0.4%
NASDAQ TLSIW traded up $0.00 during trading hours on Tuesday, hitting $0.94. 1,826 shares of the company’s stock were exchanged, compared to its average volume of 4,839. The stock has a 50-day simple moving average of $0.87 and a 200 day simple moving average of $0.95. TriSalus Life Sciences has a 1-year low of $0.44 and a 1-year high of $1.85.
About TriSalus Life Sciences
TriSalus Life Sciences is a medical technology and therapeutics company focused on improving treatment delivery for patients with solid tumors, particularly tumors in the liver and pancreas. Its approach combines proprietary drug-delivery technology with the development of immunotherapies. The company’s TriNav® infusion system is designed to deliver therapies into tumors using its Pressure-Enabled Drug Delivery (PEDD) approach. TriSalus is also developing investigational therapies intended to work alongside its delivery platform; these therapies are not established treatments.
Further Reading
- Five stocks we like better than TriSalus Life Sciences
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
